GEM 21S Equimatrix Heli Products Mucograft References Download Center Video Education Center Lecture Materials
Professionals Patients Contact Us About Us
GEM 21S®
Why Use Equimatrix®?
Case Studies
Directions for Use
Heli Products

Why Use Equimatrix®?


Product Characteristics


Equimatrix® natural bone mineral matrix is a natural bone graft substitute derived from equine bone utilizing a unique purification process that removes all organic matter and ensures the highest level of safety for your patients.


The bone used to make Equimatrix® undergoes a series of rigorous heating and washing treatments that result in a consistently pure product.


Complex porous structure

The nano-crystalline surface of Equimatrix® seen under high power scanning electron microscopy has been demonstrated to have a high affinity for osteoblast cell attachment.  Cellular attachment to the bone matrix is a critical precursor to successful regeneration of new bone.


Scanning electron microscopy at 700x Scanning electron microscopy at 2,500x Scanning electron microscopy at 50,000x


Similarity to human bone

The complex, porous network found in Equimatrix® closely resembles natural human bone and results in excellent osteoconductive properties of the material.


Equimatrix® Human bone



Scientific Evidence: Canine Intrabony Defect Study1



To evaluate the bone regenerative capacity of Equimatrix® in a canine intrabony defect model.



Mandibular second an fourth premolars were extracted from 12 adult dogs;

  • Periodontal probing depth was measured manually at the proximal sites of the mandibular third molar prior to defect creation.
  • Two-walled intrabony defects (5x5x5 mm) were surgically created on the mesial and distal side of the mandibular third premolars
  • The 48 defects were then randomly asigned into one of the following treatment groups:
    • Equimatrix® plus Bio-Gide®
    • Bio-Oss® plus Bio-Gide®
    • Bio-Gide® only
    • No treatment (control)
  • Block sections and micro-CT scans of the defect sites were collected at 10, 16, 24 weeks after checking periodontal probing depth

Histomorphometric Results:





































Results: Histologic Analysis

The intrabony defects in the control and membrane only (Bio-Gide®) groups showed mostly fibrous tissue with little evidence of new bone. In the Equimatrix® and Bio-Oss® groups, similar results were obtained in terms of new bone growth, remaining graft particles and connective tissue percentages.









Equimatrix®  + Bio-Gide® 40x Bio-Oss® + Bio-Gide® 40x

Histologic view of Equimatrix® 

at 24 weeks. Magnification 40x. (E=Equimatrix®; NB=new bone; NC=new cementum)

Histologic view of Bio-Oss® at 24 weeks. Magnification 40x. (B=Bio-Oss®; NB=new bone; NC=new cementum)


Equimatrix® + Bio-Gide® 100x Bio-Oss® + Bio-Gide® 100x

Histologic view of Equimatrix®

at 24 weeks. Magnification 100x. (E=Equimatrix®; NB=new bone; NC=new cementum; PDL=periodontal ligament)

Histologic view of Bio-Oss®

at 24 weeks. Magnification 100x. (B=Bio-Oss®; NB=new bone; NC=new cementum; PDL=periodontal ligament)


1 Kim TI, Lee SC, Park YJ, Rhee SH, Chung CP. Experimental study on the bone regenerative capacity of equine bone mineral in canine alveolar bone defects. Journal of Periodontal & Implant Science 2011; 410 (5).


Bio-Oss and Bio-Gide are a registered trademarks of Ed. Geistlich Sohne Ag Fur Chemische.

Osteohealth Company   |   Contact Us   |   © 2014 Luitpold Pharmaceuticals, Inc. Company   |   Privacy Policy   |   Terms of Use

June 29, 2016 – Effective today, Ken Keller has been newly appointed as President and CEO of Luitpold Pharmaceuticals, in addition to his current position as President, Daiichi Sankyo Administrative and Commercial, Daiichi Sankyo, Inc.

With more than 25 years of experience in the pharmaceutical industry in commercial leadership and joint venture leadership, Mr. Keller will now oversee both the Daiichi Sankyo, Inc. Commercial organization and Luitpold Pharmaceuticals, Inc.

Mr. Keller joined Daiichi Sankyo, Inc. in 2014 and has also served on the Luitpold Board of Directors since 2015. He has successfully led the Daiichi Sankyo, Inc. US commercial organization as it begins its transformation to a specialty focused company.

“While Luitpold and Daiichi Sankyo US businesses serve different customers and markets, they each bring to the table important strengths and focus that are essential to the continued success and growth of the Daiichi Sankyo Group,” said Ken Keller. “I look forward to working with the Luitpold team and driving even further success in the future.”

Luitpold Pharmaceuticals, Inc. is a Daiichi Sankyo Group Company headquartered in Shirley, NY, and manufactures more than 80 pharmaceutical products.